

# Geminin Is Required for Epithelial to Mesenchymal Transition at Gastrulation

Lisa S.D. Emmett and K. Sue O'Shea

Geminin is a multifunctional protein previously suggested to both maintain the bone morphogenetic protein inhibition required for neural induction and to control cell-cycle progression and cell fate in the early embryo. Since Geminin is required in the blastocyst on E3.5, we employed shRNA to examine its role during post-implantation development. *Geminin* knockdown inhibited the epithelial to mesenchymal transition (EMT) required at gastrulation and neural crest delamination, resulting in anterior-posterior axis and patterning defects, while overexpression promoted EMT at both locations. Geminin was negatively correlated with expression of E-cadherin, which is critically involved in controlling epithelial architecture. In addition, *Geminin* expression level was correlated with Wnt signaling and expression of the Wnt target gene *Axin2* and with *Msx2*, and negatively correlated with the expression of *Bmp4* and *Neurog1* in quantitative reverse transcriptase-polymerase chain reaction analysis of RNAs from individual embryos. These results suggest that in addition to patterning the early embryo, Geminin plays a previously unrecognized role in EMT via its ability to affect Wnt signaling and E-cadherin expression.

## Introduction

THE EPIBLAST IS PATTERNED by reciprocal signaling between embryonic and extra-embryonic tissues to first position the proximal-distal (PD) axis; the anterior migration of the distal visceral endoderm then breaks the radial symmetry of the embryo and establishes the anterior-posterior (AP) axis [1,2]. At the onset of gastrulation, cells at the posterior pole of the epiblast divide and move medially in the primitive streak [3]. Subsequent epithelial to mesenchymal transition (EMT) and formation of the 3 definitive germ layers depend on the convergence of multiple signal transduction pathways to downregulate E-cadherin [4], and control the ensuing expression of genes involved in cell migration and in lineage differentiation. The ectoderm is then patterned by controlled bone morphogenetic protein (BMP) signaling [5], although additional molecules are likely required in the mammalian embryo [6].

One candidate previously identified, based on its ability to affect the size of the *Xenopus* neural plate [7], is the 33 kDa protein Geminin. Geminin has been suggested to act as a switch between proliferation and differentiation of many tissues [8–10] and certain cancers [11,12] presumably via its ability to control cell-cycle progression by associating with Cdt1 [13]. Despite its provocative function in *Xenopus* embryos, the role of Geminin during early mammalian development is largely unknown since deletion is lethal on E3.5 of development [14,15] due to over-replication of DNA.

In the postimplantation embryo, *Geminin* is expressed initially in the epiblast at E6.5; with neural induction and gastrulation, *Geminin* is present in the neural plate and primitive streak, while extra-embryonic tissues and the epidermal ectoderm consistently lack *Geminin*. To examine its role in development, we overexpressed a *Geminin* cDNA or employed shRNAs to knockdown *Geminin* expression. As *Geminin* expression decreased, Wnt signaling and *Bmp4* expression were attenuated, while overexpression expanded both. *Geminin* shRNA embryos also failed to initiate *Fgf8* expression in the primitive streak and E-cadherin was strikingly upregulated, abrogating EMT and gastrulation movements. Cell migration through the node and primitive streak was affected, inhibiting AP axis elongation and producing defects of neural tube and body wall closure. Conversely, overexpression attenuated E-cadherin expression, promoting premature EMT at both the primitive streak and neural crest. These results identify a novel role for Geminin in EMT and highlight the central role of this transition in development, metastasis, and recently, in cellular reprogramming.

## Materials and Methods

### Mice

Time-pregnant ICR strain (Harlan) or “Wnt indicator” mice expressing  $\beta$ -galactosidase via 6 transcription factor/lymphoid enhancer binding factor (TCF/LEF) sites [16] were employed and embryos harvested on E6.5–E17.0. To monitor

the health status of pregnant dams after shRNA exposure, blood chemistries were analyzed by Unit for Laboratory Animal Medicine (ULAM) Pathology Core and did not identify significant variations in health profile. All protocols were reviewed and approved by the University of Michigan Committee on the Use and Care of Animals.

### DNA delivery

E6.0 time-pregnant mice were injected via the tail-vein with 5  $\mu$ g each of 2 shRNAs targeting *Geminin* or scrambled hairpin control shRNA constructs (Supplementary Fig. S1; Supplementary Data are available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)) in 150  $\mu$ L Ringer's solution as previously described [17]. For overexpression, the US2 promoter drove a *Geminin* cDNA and enhanced green fluorescent protein (EGFP). shRNA targeting *Geminin* or scrambled control shRNA was also injected into the pronucleus of fertilized zygotes, (C57BL/6 $\times$ SJL)F2 by the University of Michigan Transgenic Animal Core. Embryos were transferred to pseudopregnant dams and allowed to develop to E6.5–E9.5.

### Tissue analysis

Mice were sacrificed, embryos dissected from amnion and chorion, and digital images obtained prior to fixation. For whole-mount immunohistochemistry and whole-mount in situ hybridization (WISH), embryos were fixed for 10 min in 2% PFA. Embryos for WISH were dehydrated in MeOH, then stored at  $-20^{\circ}\text{C}$ . For SEM, embryos were fixed in 1% glutaraldehyde, dehydrated, followed by hexamethyldisilazane, and then examined in an Amray 1910 SEM. Individual embryos for quantitative reverse transcriptase–polymerase chain reaction (qRT-PCR) were placed in Trizol (ILT), and those for western blot analysis were placed in RIPA/7 $\times$  complete buffer (Roche) and stored at  $-20^{\circ}\text{C}$ .

### Quantitative RT-PCR

RNAs were extracted using Trizol. To minimize variation, control embryos were carefully staged: Stage 1: primitive streak (E7.0) to 4–5 somites; Stage 2: 5–10 somites; Stage 3: 10–12 somites; Stage 4: 12–25 somites. RNAs were also collected from blastocyst, E11, E13, E15, and E17 staged embryos, from individual Stage 3 and Stage 4 embryos exposed to *Geminin* shRNA ( $n=7$  and  $n=30$ ), scrambled shRNA ( $n=10$  and  $n=22$ ), or to the *Geminin* cDNA (Stage 4,  $n=36$ ) and reverse transcribed using 1  $\mu$ g RNA and random nonamers. qRT-PCR was performed in triplicate using iQ SYBR green supermix (BioRad) with  $\beta$ -actin as a reference. Primer sequences are provided in Supplementary Table S1. Mean control Ct values were used as the reference for embryos exposed to *Geminin* shRNA or cDNAs, and fold changes calculated [18].

### Western blotting

Individual E9.0 embryos were homogenized, protein quantified using the Bradford reagent (BioRad), subjected to polyacrylamide gel electrophoresis, and exposed to *Geminin* (1:1000; Santa Cruz sc-13015),  $\beta$ -actin (1:20,000; Sigma #A1978), and E-cadherin (1: 200; Cell Signaling) antibodies. Exposure to rabbit anti-HRP (1:2000) and mouse anti-HRP

(1:20,000; Jackson Immunoresearch) was followed by detection in luminol (Supersignal West pico chemiluminescent substrate, Thermo Scientific) and exposure to film for 1 min. Band intensity was determined using a BioRad ChemiDoc.

### Statistical analysis

Expression data were analyzed using Student's *t*-test, with linear regression analyses of western blot and qRT-PCR data using SPSS.

### Immunohistochemistry

Embryos were exposed to primary antibody overnight at  $4^{\circ}\text{C}$  followed by appropriate secondary antibodies. Primary antibodies were: Foxa2 (1:1000; Millipore #07-633), Sox3 (1:2000; MW Klymkowsky, Denver, CO), E-cadherin (1:500; BD #610181 and S Weiss, University of Michigan), laminin (1:25; Sigma #L9393), TuJ1 (1:200; Covance #MMS-435P), phospho-histone H3 (1:2000; Upstate #09-797), DsRed (1:100; SantaCruz, #SC33353), and EGFP (1:500; Abcam #42560). Secondary antibodies were conjugated to Alexa-488 (1:1000), Texas Red (1:500), FITC (1:500), or HRP (1:200) (Jackson Immunoresearch Laboratories). Hoechst 33258 (1  $\mu$ M) was used to identify nuclei. X-gal staining was carried out ([www.sanger.ac.uk/genetrap/](http://www.sanger.ac.uk/genetrap/)) with 20  $\mu$ g/ $\mu$ L X-gal (ILT #15520-034). TUNEL staining was carried out following the manufacturer's protocol (Promega). Images were captured using an Olympus BX-51, Leica dissecting scope, Leitz Fluovert, and/or a Zeiss 541 confocal microscope and transferred to Photoshop to assemble plates.


### Whole-mount in situ hybridization

Embryos were treated with proteinase K, and WISH was carried out [19]. Probes were generated using T3 or T7 polymerase and DIG-11-UTP labeling kit (Roche). A 412 bp-*Geminin* probe was generated by linearizing pSK using BsaI and transcribing with T3 polymerase (NM\_020567 nt 564 to 976). The 751 bp-*Brachyury* probe was first linearized from pSK by Xho 1 and transcribed using T3 (NM\_009309 nt 476 to 1227). Additional probes used were obtained from *Bmp4* [20], *Cer1* [21], *Engrailed-2* [22], *Hesx1* [23], *Shh* [24], *Fgf8* [25], *Msx2* [26], *Snail1* [4], and *Nodal* [27]. Detection was carried out using anti-DIG-AP and NBT/BCIP (Roche). After photography as whole mounts, 10 micron frozen sections were cut and photographed.

## Results

### *Geminin* expression is initially restricted to the epiblast, primitive streak, and neural ectoderm

*Geminin* mRNA was present in the epiblast and forming neural ectoderm (Fig. 1A–C), expression terminating sharply at its boundary with the epidermal ectoderm (Fig. 1B, C arrow). It was expressed in the primitive streak (Fig. 1A, C) and dorsal node (Fig. 1A, B arrowheads) on E7.5, but was not present in extra-embryonic tissues at any stage examined (Fig. 1). By E8.5 and E9.5, *Geminin* was expressed throughout the neural ectoderm (Fig. 1D–I, E double arrows), but continued to be excluded from the epidermal ectoderm (Fig. 1D–F, I arrows), from the endoderm, and the heart. Overall, mRNA expression peaked at 5–10 somites, declining until E13 then increasing during organogenesis (Supplementary Fig. S3A).



**FIG. 1.** *Geminin* expression. Whole-mount in situ hybridization localization of *Geminin* mRNA in control embryos on E7.5 (A-C), E8.5 (D-F), and E9.5 (G-I); in E8.5 *Geminin* shRNA embryos (J-L) and E8.5 *Geminin* overexpressing embryos (M-O). A, allantois; H, heart; Hf, headfolds; NE, neural ectoderm; ntc, notochord; ov, otic vesicle; pnp, posterior neuropore; PS, primitive streak; arrowhead in A, B, node; arrow in B, C, D, E, F, I, N, epidermal ectoderm; dashed line in B, edge of epidermal ectoderm; double arrows in E, *Geminin* expression in the neural tube. Anterior is to the left in: A, D, G, J, M. Anterior (coronal) views: B, E. Dorsal views: F, H, K, N. Transverse sections with anterior at top: C, I, L, O. Scale bars = 200  $\mu$ m except (C, L, O) which are 100  $\mu$ m. Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)



### *Geminin* expression can be modified by exposure to *Geminin* shRNA or a *Geminin* cDNA

shRNA to knockdown or a *Geminin* cDNA to overexpress *Geminin* were delivered to pregnant dams on E6.0 [28,29]. Additional embryos were injected at the pronuclear stage with either an shRNA or a scrambled control shRNA (Supplementary Fig. S1). Little mRNA was detected in shRNA embryos (Fig. 1J–L), while exposure to the *Geminin* cDNA (Fig. 1M–O) increased *Geminin* mRNA in the neural ectoderm, but not heart or epidermal ectoderm (Fig. 1N arrow), possibly regulated by the many microRNAs that may target *Geminin*. Immunohistochemical localization of DsRed or EGFP indicated that the plasmids were widely expressed in postimplantation embryos, with considerable overlap with Hoechst 33258 (Supplementary Fig. S2).

shRNA exposure significantly reduced *Geminin* mRNA expression (>6-fold,  $P < 0.001$ ) compared with scrambled shRNA embryos, while the *Geminin* cDNA increased expression by 6.2-fold ( $P < 0.001$ ; Supplementary Fig. S3B). *Geminin* protein was 134.1% of control expression after cDNA exposure and 54.4% of control levels ( $P < 0.001$ ) after shRNA-treatment (Supplementary Fig. S3C and Table 1); individual embryos exhibited a range in *Geminin* protein from control levels to virtually no protein (Supplementary Fig. S3D). This technique can produce graded knockdown similar to electroporation or to an allelic series with a corresponding range of phenotypes within a litter (Supplementary Fig. S4).

### *Geminin* is required during preimplantation development

Pronuclear injection of shRNA produced significant preimplantation loss with surviving embryos (18%) often exhibiting few anomalies (Supplementary Fig. S1G–I). However, by delivering the shRNAs on E6.0 to bypass the early requirement for *Geminin*, we were able to obtain knockdown in more than 70% of the embryos.

### *Geminin* is required in the epiblast for axis elongation and neurulation

By E7.5, control embryos had well-organized neural folds and an expanded amniotic cavity as a result of normal axis elongation (Supplementary Fig. S1A). In *Geminin* shRNA-exposed embryos (Supplementary Fig. S1D), the node was positioned anteriorly and AP axis elongation was inhibited, like the rare surviving embryos after pronuclear injection of shRNA (Supplementary Fig. S1G). *Geminin* overexpression

was often lethal; surviving embryos (Supplementary Fig. S1J) were often composed of headfolds and membranes with disorganized posterior tissues.

By E8.5, compared with control embryos (Supplementary Fig. S1B), the anterior- and posterior neuropores of shRNA embryos remained widely open (Supplementary Fig. S1E, H). Overexpression of *Geminin* resulted in posterior disorganization with relatively well-formed headfolds (Supplementary Fig. S1K). When E9.0 embryos were examined using SEM, the anterior neural folds of controls were approaching the dorsal midline (Supplementary Fig. S5A, D, G) compared with shRNA- and cDNA-exposed embryos, where the neural folds were widely everted (Supplementary Fig. S5B, C, E, F, H, I) and massively overgrown in overexpressing embryos (Supplementary Fig. S5C, F, I). The proepicardium, which also undergoes EMT, failed to cover the heart tube of shRNA embryos (Supplementary Fig. S5H). By E9.5, the anterior neural tube had closed in control embryos (Supplementary Fig. S1C), while shRNA embryos often had open, everted neural folds (Supplementary Fig. S1F arrows). The first branchial arch was also small and abnormally oriented. Surviving embryos carrying the hairpin shRNA express DsRed or EGFP (Supplementary Figs. S1F, I, S2D, G). Embryos that survived *Geminin* overexpression to E9.5 often failed to undergo the normal turning process and the neural ectoderm was overgrown (Supplementary Fig. S1L arrows).

### *Geminin* is required for morphogenetic cell movements at gastrulation

At gastrulation, cells delaminate from the primitive streak to form endoderm by intercalating and replacing the primitive endoderm (PE) with definitive (embryonic) endoderm (DE) [30]. As gastrulation proceeds, the boundary between the PE and DE progresses from distal to proximal, terminating at the extra-embryonic margin (Fig. 2A, C asterisks; 2C dashed line in inset). In *Geminin* shRNA embryos, this boundary failed to migrate (Fig. 2B, D asterisks) suggesting that DE does not replace PE. PE markers including HRP, illustrate a similar lack of cell movement (not shown) indicating that *Geminin* is required for differentiation or migration of the DE.


Compared with control embryos (Fig. 2A, C, E), both the foregut and hindgut pockets were widely open in shRNA embryos (Fig. 2B, D, F), likely due to the lack of elongation and morphogenetic movements required for body wall closure. *Foxa2* was expressed in the DE that lines the node and foregut pocket (Fig. 2E, F), highlighting the widely open foregut pocket, shortened anterior-posterior axis, and abnormal headfold positioning in shRNA embryos (Fig. 2F).

TABLE 1. REGRESSION ANALYSIS

Group	<i>E-cadherin</i>	<i>Geminin</i>	Ratio	$R^2$	$f$	$P <$	$T$
Pooled embryos			1.3	0.001	0.77	0.00001	5.48
Missense	99.8+7.7	100.2+12.6	0.99	0.275	0.02	0.0009	4.8
shRNA	202.3+26.8	54.4+4.7	3.72	0.776	0.00	0.021	-2.4
OE	65.2+5.6	134.1+15.0	0.49	0.15	0.02	0.00008	4.74

*E-cadherin* expression is inversely correlated with *Geminin* protein levels. Regression analysis of individual embryos after knockdown or overexpression of *Geminin* in comparison to *E-cadherin* expression.

OE, overexpressing.



**FIG. 2.** Alterations at the node. E7.5 embryos exposed to scrambled shRNA (A, C, E, G) or to *Geminin* shRNA (B, D, F, H) were analyzed using SEM or Foxa2 expression in sagittal sections (E, F). Arrowheads (A–F), node; \* (A–D), border of PE and DE; white arrowhead (G, H), ciliated cells of the node; black arrowheads (H), aggregate of cells at the node; f, foregut pocket; Hf, headfolds; PS, primitive streak. Anterior view in A, B; Anterior is to the left in C–F; Distal tip of the embryo toward the top in G, H (inset is posterior to anterior orientation). Scale bars = 100  $\mu$ m (A–D, G, H), 10  $\mu$ m (inset in C), and 200  $\mu$ m (E, F). PE, primitive endoderm; DE, definitive endoderm. Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)

### Loss of *Geminin* affects cell migration through the node


Normally, the node has a slightly concave appearance (Fig. 2A, E, G); cells at the tip involute as the AP axis elongates and the node moves posteriorly [31]. When *Geminin* expression was downregulated, the node failed to regress, forming a deep, concave pit (Fig. 2B, H white arrowheads), leaving a cluster of unorganized cells behind (Fig. 2H black arrowheads). However, *Nodal* expression in the surrounding crown cells was not affected by *Geminin* dosage (not shown).

### *Geminin* is required for EMT at gastrulation

The primitive streak is a pseudostratified epithelium from which mesoderm cells delaminate at the midline (Fig. 3A arrowhead). In shRNA embryos, cells fail to leave the primitive streak resulting in an overgrown epiblast (Fig. 3E white arrow), while *Geminin* overexpression resulted in premature EMT and disorganization of the posterior pole of the embryo (Fig. 3I). In control embryos, E-cadherin expression decreased at the midline (Fig. 3B, arrowhead); however, in *Geminin* shRNA embryos E-cadherin persisted in the primitive streak, mesoderm, and endoderm (Fig. 3F arrowhead). In overexpressing embryos, there was less E-cadherin in the epithelium and the newly formed mesoderm, whereas it remained at high levels in the PE (Fig. 3J arrows). Laminin, which is expressed in the basement membrane of the ectoderm except the midline of the primitive streak where cells ingress, was also affected by *Geminin* dose. When *Geminin* was overexpressed, the normally linear pattern of laminin immunoreactivity was irregular and punctate, while in knockdown embryos it remained in the basement membrane throughout its extent. In immunoblots of protein from individual embryos, *Geminin* protein was strongly negatively correlated with E-cadherin levels (Fig. 3M, N; discussion below).


X-gal staining of control “Wnt indicator” embryos [16] indicated that Wnt signaling was normally tightly restricted to the primitive streak (Fig. 3C, D). However, in *Geminin* shRNA embryos, signaling was reduced (Fig. 3G, H), while overexpression expanded the Wnt-signaling domain into the mesoderm (Fig. 3K, L). The early expression of *Bmp4* in the extra-embryonic ectoderm and epidermal ectoderm of control embryos (Fig. 4A) was expanded in shRNA embryos, (Fig. 4G), suggesting that *Bmp4* (and *Nodal*) are expressed at sufficient levels to position the node, but *Geminin* is required to constrain the *Bmp4* expression domain as in *Xenopus* [7].

In control embryos, *Cer1* and *Hesx1* were expressed in the anterior endoderm (Fig. 4B, C); *Geminin* knockdown expanded their expression domains posteriorly (Fig. 4H, I). *Fgf8* and *Snail1* were present in the primitive streak of control embryos (Fig. 4D, E); but they were down regulated in *Geminin* shRNA embryos (Fig. 4J, K). *Brachyury*, present in early mesoderm of the primitive streak and node (Fig. 4F), had a slightly wider expression domain near the allantois of shRNA embryos (Fig. 4L). In transverse section, *Brachyury* is expressed in the primitive streak and newly forming mesoderm in missense control embryos (Fig. 7J), compared with shRNA embryos, where there is little mesoderm and strong ectodermal expression (Fig. 7N).



**FIG. 3.** Organization of the primitive streak. The primitive streak of control embryos (A–D), *Geminin* shRNA embryos (E–H), and *Geminin* overexpressing embryos (I–L) was analyzed using SEM of transverse fractures (A, E, I), E-cadherin localization in transverse sections (B, F, J), and  $\beta$ -gal expression in “Wnt-indicator” mice (C, D, G, H, K, L). Anterior is to the left in C, G, K. D, H, L are transverse sections at levels indicated in C, G, and K with anterior at top. A, allantois; E, ectoderm; En, endoderm; M, mesoderm; PS, primitive streak; arrowhead (A–B, E–F, I–J), primitive streak; arrowhead (C, G, K), node; white arrow (E), overgrown epiblast. Scale bars = 100  $\mu$ m (A, B, E, F, I, J), 200  $\mu$ m (C, D, G, H, K, L). M. Western blot analysis of the relative expression of E-cadherin in scrambled shRNA control, *Geminin* shRNA-exposed embryos and embryos overexpressing (OE) *Geminin*. E-cadherin expression is inversely related to *Geminin*. \* $P < 2.1 \times 10^{-8}$ , \*\* $P < 0.02$ , \*\*\* $P < 2.6 \times 10^{-14}$ , Student's *t*-tests. N. Representative western blots illustrating E-cadherin, *Geminin*, and  $\beta$ -actin in individual E9.0 embryos exposed to scrambled (lane 1), *Geminin* shRNA (lane 2), or *Geminin* overexpression (OE; lane 3) constructs. Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)





**FIG. 4.** Geminin is required to pattern the embryo on E7.5. Whole-mount in situ hybridization was used to analyze gene expression in E7.5 control (A–F) and *Geminin* shRNA (G–L) embryos. Embryos were hybridized with probes to: *Bmp4* (A, G), *Cer1* (B, H), *Hesx1* (C, I), *Fgf8* (D, J), *Snail1* (E, K), and *Brachyury* (F, L). Anterior is oriented to the left in all images except (F, L), which are posterior (ventral) views. A, allantois; Hf, headfolds; PS, primitive streak; arrowhead, node. Scale bars = 200  $\mu$ m for all embryos. Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)

### *Geminin* dose controls neural crest EMT

Combinatorial signaling by Wnts, BMPs, and fibroblast growth factors (FGFs) is thought to specify the neural crest [32]. In control embryos, *Snail1* and *Msx2* were expressed at the margins of the neural folds and by neural crest cells (NCC) migrating into the mesenchyme (Fig. 5A, J) in both the cephalic region (Fig. 5D, M) and the posterior neuropore (Fig. 5G, P). *Msx2* was also expressed in the lateral plate mesoderm that will line the body wall and gut tube (Fig. 5M, P), and *Snail1* in the extra-embryonic mesoderm of the allantois (not shown). In *Geminin* shRNA embryos, expression of both genes was strikingly downregulated in the anterior neural crest and mesenchyme (Fig. 5B, E, K, N arrow), although some *Snail1* was present in NCC in the branchial arches (Fig. 5E arrow). The posterior neuropore was often flattened and there was little *Snail1* expressed in this region (Fig. 5H), or in the allantois (not shown). *Msx2* was similarly strongly downregulated in the posterior region although there was ectopic expression of *Msx2* in the aggregate of cells at the junction of the posterior neuropore with the primitive streak (Fig. 5Q arrowheads). Overexpression of *Geminin* increased *Snail1* (Fig. 5C, F) and *Msx2* (Fig. 5L, O) in NCC. Both were strongly expressed in the mesenchyme of the headfolds and branchial arches (Fig. 5F, O arrows), the posterior neuropore (Fig. 5I, R arrows), and allantois (not shown). *Geminin* dose did not produce alterations in either proliferation or cell death (not shown), however.

### *E-cadherin* expression is negatively correlated with *Geminin* level

Given the striking changes in E-cadherin expression in the embryo in immunohistochemistry, and the central role of E-cadherin in controlling EMT, we quantified E-cadherin protein from individual embryos using western blot. Geminin expression level was normalized to  $\beta$ -actin to control loading, then compared to E-cadherin. Geminin was expressed at highest levels in single overexpressing embryos and significantly decreased in shRNA-treated embryos (Table 1). E-cadherin was reciprocally expressed; E-cadherin was high in shRNA-exposed embryos and significantly decreased when Geminin levels were increased. We examined

the relationship between E-cadherin and Geminin first using ratios (Table 1 and Fig. 3M, N); the means were significantly different between the groups when analyzed using *t*-test. Data were also analyzed using regression analysis. When data from all embryos were pooled, there was a consistent significant correlation in Geminin expression level and the expression of E-cadherin ( $P \leq 0.00001$ ,  $t = 5.479$ ). Within treatment groups, the correlations were positive, except in the shRNA embryos where high E-cadherin was associated with low levels of Geminin expression.


### *Wnt* signaling is responsive to *Geminin* dosage

On E9.5, Wnt signaling was active in the dorsal rhombencephalon, midbrain, and forebrain (Fig. 6A, D, G), in NCC migrating to the first branchial arch, differentiating somites, and posterior neuropore (Fig. 6A arrowhead). *Geminin* shRNA decreased  $\beta$ -gal expression throughout the embryo (Fig. 6B), but particularly in migrating NCC, in the forebrain and midbrain (Fig. 6B, E, H), the forming proepicardium (Fig. 6B, asterisk), and posterior neuropore (Fig. 6B arrowhead). Overexpression strikingly elevated signaling throughout the neuraxis, particularly in the first arch, the midbrain, and the hindbrain (Fig. 6C, F, I) and in somites and the posterior neuropore (Fig. 6C, F).

### *Anterior and posterior patterning is affected by Geminin* knockdown


In control embryos, *Shh* is expressed in the node and notochord from the posterior pole of the embryo to the commissural plate (Fig. 7A–C). In shRNA embryos, there was patchy expression of *Shh* in the notochord, (Fig. 7E, F) producing a widened floor plate and neural tube closure abnormalities (Fig. 7F, G, M, O). Unlike controls (Fig. 7D), *Shh* was not expressed in the liver bud of shRNA embryos (Fig. 7H), which would affect later differentiation of both the liver and gall bladder.

By E9.5, the posterior neuropore (pnp) was closing (Fig. 7I) and *Brachyury* expression was restricted to this region (Fig. 7J, J'). In contrast, the pnp was consistently widely-open in shRNA embryos (Fig. 7M) and *Brachyury* expanded into the dorsal wall of the hindgut (Fig. 7N, N'). There was decreased



**FIG. 5.** *Geminin* dose controls expression of *Snail1* and *Msx2*. Localization at E8.5 of *Snail1* (A–I) and *Msx2* (J–R) in control (A, D, G, J, M, P), *Geminin* shRNA (B, E, H, K, N, Q) and overexpressing embryos (C, F, I, L, O, R) in transverse sections of the anterior neural folds (D–F, M–O), or posterior neuropore (G–I, P–R). A, allantois; cp, commissural plate; H, heart; Hf, headfolds; pnp, posterior neuropore. Arrows indicate NCC in D–I, M–O. In P–R arrowheads identify clusters of cells at the junction of the pnp and primitive streak. White arrows indicate ectopic *Msx2* expression. Anterior is to the left in: A–C, J–L. Anterior toward the top in: D–I, M–R. Scale bars = 200  $\mu$ m (A–C, J–L); 100  $\mu$ m (D–I, M–R). Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)





**FIG. 6.** *Geminin* dose affects Wnt signaling. Embryos were exposed to scrambled (A, D, G), *Geminin* shRNA (B, E, H), or *Geminin* overexpression (C, F, I) constructs followed by X-gal staining to identify sites of Wnt signaling. (A–C) Sagittal views of E9.5 embryos with anterior to the left. (D–F) Dorsal views. (G–I) Coronal sections through the midbrain. \*Proepicardium; 1, first branchial arch; H, heart; Hf, head folds; arrowhead, posterior neuropore. Scale bars = 200  $\mu$ m (A–F), 100  $\mu$ m (G–I). Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)

*Fgf8* expression in the wide ventral commissural plate, and in the first branchial arch of *Geminin* shRNA embryos (Fig. 7O, O', P arrows) compared with controls (Fig. 7K, K', L). This was specific to the anterior neural folds as *Fgf8* expression in the isthmus and limb bud was unaffected by *Geminin* knockdown. *Engrailed-2*, which is normally present in the posterior midbrain and in rhombomere 1 of the hindbrain was strikingly reduced in the midbrain but not in rhombomere 1 of shRNA embryos (not shown).

#### *Geminin* alters differentiation of neural precursor cells

Prior research suggested that *Geminin* controls the switch between proliferation of neural precursors and differentiation into immature neurons [33,34]. In control embryos, *Sox3* identifies proliferative neural precursors (Fig. 8A–C), while *Tuj1* appears later in midbrain neurons (Fig. 8J–L). In shRNA embryos, *Sox3* was reduced (Fig. 8D–F) and *Tuj1* prematurely expressed throughout the neuraxis (Fig. 8M–O). Overexpression of *Geminin* also decreased *Sox3* (Fig. 8G–I), while *Tuj1* expression was increased (Fig. 8P–R). These results suggest that *Geminin* exerts stage-specific and context-dependent control of ectoderm differentiation.


#### Gene expression analysis

To correlate *Geminin* and target gene expression, we carried out qRT-PCR analysis of RNAs from individual embryos ex-

posed to shRNAs (Supplementary Table S2) and from single embryos overexpressing *Geminin* (Supplementary Table S3), followed by Pearson correlation. *Geminin* levels were positively correlated with the expression of the Wnt target *Axin2*, and negatively correlated with *Bmp4* and *Neurog1* in shRNA embryos. *Brachyury* expression was also negatively correlated with *Geminin*, but did not reach statistical significance. Interestingly, *Foxa2* was correlated with both *Sox3* and *Neurog1*, likely reflecting overall embryonic development. *Axin2* and *Neurog1* expression were also highly correlated, markers of mesoderm (*Brachyury*) and neurons (*Neurog1*) were negatively correlated, as were *Bmp4* and *Sox3* expression (Supplementary Table S2). Like our *in situ* results, *Msx2* and *Geminin* were strongly correlated in overexpressing embryos. *Bmp4* was again strongly, negatively correlated with *Sox3* expression while *Neurog1* was positively correlated with *Snail1* and *Axin2* levels (Supplementary Table S3). These results are consistent with the observed increase in *Snail1* expression in the embryo and the strong stimulation of Wnt signaling in these embryos. Overall, the most consistent effects were the strong negative correlation between *Geminin* levels with *Bmp4* and positive correlation with *Axin2*, and the negative correlation between *Bmp4* and *Sox3*.

#### Discussion

Despite its provocative prediction of the neural plate in other species [7,10,35], this is the first investigation to examine




**FIG. 7.** *Geminin* shRNA embryos are mispatterned along the length of the neuraxis. Whole-mount in situ hybridization was used to analyze the expression of *Shh* (A–H), *Brachyury* (J, N), and *Fgf8* (K, L, O, P) with SEM employed for high-magnification views of the posterior neuropore (I, M) in control (A–D, I–L) and *Geminin* shRNA-exposed embryos (E–H, M–P). Sagittal views, with anterior to the left, include: (A–C, E–G, J, L, N, P), (K, O) are coronal (ventral) views, (I, M) are dorsal views of the closing posterior neuropore, (J', K', N', O') are transverse sections (section level indicated by \* in J, K, N, O), and (D, H) are sagittal sections through the heart and liver bud of E9.0 embryos. A, allantois; a, aorta; cp, commissural plate; g, gut; H, heart; Hf, headfold; i (L, P), isthmus; Lv, liver bud; pnp, posterior neuropore; 1, first branchial arch; black arrowhead (A, E), node; black arrowheads (F, G), misexpression of *Shh*; white arrowhead (C, D), *Shh* expression in the liver bud; black arrows (P), loss of *Fgf8* in the commissural plate and branchial arch; white arrows (B, C, F, G), *Shh* expression in the cranial region. Scale bars = 200  $\mu$ m (A–C, E–G, J–L, N–P), 100  $\mu$ m (D, H, I, J', K', M, N', O'). Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)

the expression and role of Geminin in the early post-implantation-staged mouse embryo. Geminin was originally described as a bi-functional molecule; the N-terminus implicated in neural-cell fate determination [7], the C-terminus and central regions involved in DNA replication and cell cycle progression [13] in the *Xenopus* embryo. Geminin also binds polycomb and Brahma proteins to regulate gene expression

[33,9]; it binds Hox and Six proteins to influence patterning of the embryo [8,9,36]; our *in vitro* results (Slawny and O'Shea this issue) suggest that it also binds nuclear TLEs to control the Wnt-signaling cascade. Ultimately, competition for partner proteins in a position- or stage-restricted manner may place Geminin in a unique position to influence the differentiation of many tissues.





**FIG. 8.** Geminin affects the differentiation of neurons from neural precursors. Localization of Sox3 (A–I) and TuJ1 (J–R) in control (A–C, J–L), *Geminin* shRNA (D–F, M–O), and *Geminin* overexpressing (G–I, P–R) embryos. E8.5 (A, D, G) and E9.5 (B–C, E–F, H–I, J–R) embryos were examined. (A, B, D, E, G, H, K, N, Q) are sagittal views with anterior to the left. (C, F, I, J, M, P) are coronal/ventral views and (L, O, R) are coronal sections with anterior toward the top. H, heart; Hf, headfolds; arrowhead (A–P), posterior neuropore. Scale bars = 200  $\mu$ m (A–I, J–K, M–N, P–Q), 100  $\mu$ m (L, O, R). Color images available online at [www.liebertonline.com/scd](http://www.liebertonline.com/scd)

### *Geminin* dosage controls EMT

The conversion of cells within an epithelial sheet to mesenchyme is essential in transforming the early egg cylinder into the 3-germ layer embryo at gastrulation and is reiterated and reversed multiple times during development [37,38]. EMT involves a series of well-characterized alterations in cell-cell adhesion, cell polarity, expression of integrin receptors, and cell migration [39]. Interestingly, the opposite process—mesenchymal to epithelial transition—also appears to be essential in reprogramming fibroblasts to epithelial induced pluripotent cells [40,41].

Gene targeting has established that members of the Wnt, Fgf, and transforming growth factor  $\beta$  superfamilies are essential for EMT at gastrulation [37]. Lacking Geminin, embryos fail to express *Fgf8* in the primitive streak, thereby affecting the cascade of *Msx2*, *Msx1*, and E-cadherin expression. E-cadherin is critically involved in maintaining the integrity of the epithelial sheet; downregulation is required for EMT and metastasis [38]. Our data demonstrate that at the level of the individual embryo the amount of Geminin present inversely correlates with the expression of E-cadherin. The posterior disorganization observed with *Geminin* overexpression is reminiscent of embryos where Wnt pathway members are overexpressed, resulting in premature EMT of the epiblast [42]. The *Geminin* gastrulation phenotype in KD embryos is also similar to mouse embryos lacking *Hira* [43], *Fgfr1* [44,45], *Fgf8* [46], the Nodal target *Eomesodermin* [47], and *Snail1* [48], where cells fail to leave the primitive streak. Exposure of Zebrafish embryos to *Geminin* morpholinos similarly repressed *Snail1a*; mesendodermal

cells did not delaminate, while overexpression promoted *Snail1a* production and endodermal differentiation [49], suggesting that Geminin plays a central, critical role in this cascade.

### Sequelae of EMT inhibition

Failure of EMT had many sequelae, including the lack of axis elongation after the failure of mesendoderm migration, as in our EB model (Slawny and O'Shea, this volume). Geminin appears to be required downstream of Nodal signaling, since the PD axis was initially specified properly and *Nodal* expression was not affected by Geminin dosage. Migration through the posterior streak was less affected, although ectopic *Snail1* and *Brachyury* positive cells were present in the dorsal hindgut wall in *Geminin* mutant embryos, and *Geminin* dose affected *Snail1* expression in the allantoic mesenchyme. The early migrating cardiac mesoderm also appears to be unaffected by *Geminin* dose, suggesting a cell type-, region- or stage-restricted role for Geminin in lineage allocation.

*Geminin* mutant embryos exhibit body wall closure defects after failure of morphogenetic movements and endoderm differentiation, as previously reported in Zebrafish [49]. Lack of normal anterior mesendoderm migration also resulted in the failure of DE to replace PE, and persistent signaling in the anterior region, identified by expanded *Cer1* and *Hex1* expression, which likely have long-term effects on patterning of the anterior central nervous system (CNS) [50]. Neural tube closure defects were commonly observed in *Geminin*-targeted embryos, and may result from notochord abnormalities as



secreted factors from the notochord are essential for floor-plate induction and the resulting elevation of the neural folds [51]. Inhibition of BMP signaling is then required for the formation of the dorsolateral hinge points and midline approximation of the neural folds [52], suggesting that alterations in Shh and/or BMP expression may play a role in the genesis of the observed neural tube defects.

### *Geminin and the neural crest*

Neural crest emigration has been considered a second gastrulation event [53], and neural crest versus epidermal identity is determined by BMP and Wnt signaling; intermediate levels of BMP signaling position the border [54–56]. A second mesodermal Wnt signal [57] with BMP then activates *Msx1,2* gene expression [58], which induce expression of *Twist1*, *Snail1*, and *Slug* [59] that then induce *p21*, and downregulate E-Cadherin expression to promote EMT. In fact, intermediate levels of Geminin overexpression (insufficient to induce neural markers) similarly expanded the *Twist*-positive neural crest field [7,33]. In the current investigation, *Geminin* expression level strongly affected *Bmp4*, *Snail1*, and *Msx2* gene expression and Wnt signaling by NCC.

In NCC, BMP-dependent Wnt signaling has been shown to control the transition from G1 to S by modulating intracellular levels of cyclins [60]. Premigratory NCC are arrested in G1 and enter S on delamination; repression of the G1 to S transition inhibits the EMT process [61]. The unique ability of Geminin to both modulate cell cycle, while negatively modulating E-cadherin, BMP, and Fgf gene expression and to positively regulate Wnt signaling place it in a unique position to control EMT and thereby tissue organization during development. The observation that decreased Geminin levels inhibit EMT and maintain neural crest stem cells, while overexpression promotes their migration, are similar to results in subventricular zone neural stem cells where deletion of *Geminin* promoted self-renewal and expanded the progenitor population while overexpression promoted migration and differentiation [62], suggesting that similar mechanisms may maintain these stem cell niches. The observation that Geminin controls EMT may also inform our understanding of metastasis, as *Geminin* is overexpressed in a number of tumors where it is negatively correlated with outcome [63].

### *Geminin dose affects Bmp4 and Wnt Signaling*

This is the first identification of the strong correlation between Geminin and Wnt signaling, which is required in the epiblast to position and maintain the primitive streak [64]. Overexpression of *Wnt8c* [65], interference with  $\beta$ -catenin degradation [66], or deletion of negative regulators [67,68] expand or duplicate the primitive streak, as observed with *Geminin* knockdown. Geminin and Wnts may act reciprocally since the *Geminin* promoter contains TCF-binding sites [69], Geminin may control Wnt target gene expression via *Snail1* [70], or Geminin may bind a Groucho factor to modulate Wnt signaling (Slawny and O'Shea, this volume).

Given the strong negative correlation between *Geminin* and *Bmp4* expression, the requirement for BMP signaling in

the formation of the node and primitive streak, and specification of mesoderm [71,72], interference with BMP signaling may also play a role in the gastrulation block observed in *Geminin* mutant embryos. The effect may be direct as suggested by data from amphibian [7] and chick embryos [35], or Geminin may interact with additional pathway members, for example, Smad proteins in the nucleus.

### *Neural differentiation*

Geminin has been suggested to mark the acquisition by the ectoderm of neural competence [73]. The striking lack of *Geminin* in the epidermal ectoderm suggests that Geminin may function in the ectoderm like other preneural genes, such as *Sox3* and *Zic2* that are required for the induction of neural tissue by BMP inhibition, thereby positioning the neural-epidermal ectodermal border [54,73], consistent with observations that overexpression increases and reductions in Geminin reduce the size of the neural plate in *Xenopus* [7], Zebrafish [49], and *Drosophila* [10] embryos. Geminin may then maintain proliferation in the neural ectoderm and prevent premature expression of genes involved in fate-restriction [34,35,74]. These effects are both context- and dose-dependent. In the *Xenopus* embryo, high levels of Geminin are required to induce ectopic expression of neuronal markers, while low levels of suppression did not affect neuronal fate acquisition, but promoted premature neuronal differentiation [8,74]. Our results reflect a similar dosage effect; with knockdown producing premature differentiation of midbrain neurons, consistent with the strong negative correlation between *Geminin* and *Neurog1*. High levels of expression also resulted in a loss of Sox gene expression and dysregulated expression of neuronal markers, and it is possible that *Sox3* expression was accelerated rather than abrogated. Recent reports indicate that deletion of *Geminin* in nestin+ cells of the nervous system had little effect on the number or differentiation of precursors in one case [75], while deletion expanded progenitors in the subventricular zone and overexpression promoted migration and premature differentiation [62] in another. These results, and in vitro studies in embryonic stem cells (Slawny and O'Shea, this volume) emphasize the context- and dose-dependent effects of Geminin and suggest that it may play very different roles in lineage-committed precursors versus cells with multilineage differentiation potential such as the neural crest and primitive streak.

Ultimately, Geminin's effects are likely determined by the availability of protein partners in the nucleus, such as the Brahma-related gene 1, *Brg1*, which regulates both proneural bHLH [76] and Sox gene expression [35]. *Brg1* activates Wnt reporters [77], interacts with nuclear  $\beta$ -catenin to control gene expression [78,79], and can be recruited to target gene promoters by Groucho proteins [78]. The striking correlation between *Geminin* expression, Wnt reporter activity, and target gene expression suggests that in the mouse embryo, Geminin may regulate Wnt signaling via *Brg1* or yet unidentified nuclear factors. Geminin is expressed in multiple stem cell populations—embryonic stem cells, neural stem cells, the primitive streak, and gut stem cells, and overexpression in tumors is strongly negatively correlated with survival. Additional study of Geminin's role in tissue-type transitions involved in the morphogenesis of other organs

will likely require reconstruction in tissue restricted or inducible systems.

### Acknowledgments

We are grateful to: MW Klymkowsky (Sox3 antibody), S Weiss (E-cadherin antibody), A Joyner (En-2 probe), SG Gong (Bmp4), V Kaartinen (Snail1), Y Mishina (Cer1 and Hex3), P Gage (Msx2, Nodal, Fgf8, and Shh probes as well as Wnt reporter mice), and T Saunders, M Van Keuren in the University of Michigan Transgenic Animal Core. Also: Christine Belzyt, Kate Eaton, Amanda Evans-Zacharias, Theresa Gratsch, Maria Morell, John O'Shea, Nicole Slawny, Yao-Chang Tsan, and Derrick Yang for assistance, reagents, and comments on this work. This research was supported by NIH grant RR-023187.

### Author Disclosure Statement

No competing financial interests exist.

### References

1. Thomas P and R Beddington. (1996). Anterior primitive endoderm may be responsible for patterning the anterior neural plate in the mouse embryo. *Curr Biol* 6:1487–1496.
2. Arnold SJ and EJ Robertson. (2009). Making a commitment: cell lineage allocation and axis patterning in the early mouse embryo. *Nat Rev Mol Cell Biol* 10:91–103.
3. Lawson KA, JJ Meneses and RA Pedersen. (1991). Clonal analysis of epiblast fate during germ layer formation in the mouse embryo. *Development* 113:891–911.
4. Cano A, MA Perez-Moreno, I Rodrigo, A Locascio, MJ Blanco, MG del Barrio, F Portillo and MA Nieto. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* 2:76–83.
5. Levine AJ and AH Brivanlou. (2007). Proposal of a model of mammalian neural induction. *Dev Biol* 15:247–256.
6. Bachiller D, J Klingensmith, C Kemp, JA Belo, RM Anderson, SR May, JA McMahon, AP McMahon, RM Harland, J Rossant and EM De Robertis. (2000). The organizer factors Chordin and Noggin are required for mouse forebrain development. *Nature* 403:658–661.
7. Kroll KL, AN Salic, LM Evans and MW Kirschner. (1998). Geminin, a neuralizing molecule that demarcates the future neural plate at the onset of gastrulation. *Development* 125:3247–3258.
8. Del Bene F, K Tessmar-Raible and J Wittbrodt. (2004). Direct interaction of geminin and Six3 in eye development. *Nature* 427:745–749.
9. Luo L, X Yang, Y Takihara, H Knoetgen and M Kessel. (2004). The cell-cycle regulator geminin inhibits Hox function through direct and polycomb-mediated interactions. *Nature* 427:749–753.
10. Quinn LM, A Herr, TJ McGarry and H Richardson. (2001). The Drosophila Geminin homolog: roles for Geminin in limiting DNA replication, in anaphase and in neurogenesis. *Genes Dev* 15:2741–2754.
11. Dudderidge TJ, K Stoeber, M Loddo, G Atkinson, T Fanshawe, DF Griffiths and GH Williams. (2005). Mcm2, Geminin, and Ki67 define proliferative state and are prognostic markers in renal cell carcinoma. *Clin Cancer Res* 11:2510–2517.
12. Xouri G, Z Lygerou, H Nishitani, V Pachnis, P Nurse and S Taraviras. (2004). Cdt1 and geminin are down-regulated upon cell cycle exit and are over-expressed in cancer-derived cell lines. *Eur J Biochem* 271:3368–3378.
13. McGarry TJ and MW Kirschner. (1998). Geminin, an inhibitor of DNA replication, is degraded during mitosis. *Cell* 93:1043–1053.
14. Gonzalez MA, KE Tachibana, DJ Adams, L vander Weyden, M Hemberger, N Coleman, A Bradley and RA Laskey. (2006). Geminin is essential to prevent endoreplication and to form pluripotent cells during mammalian development. *Genes Dev* 20:1880–1884.
15. Hara K, KI Nakayama and K Nakayama. (2006). Geminin is essential for the development of preimplantation mouse embryos. *Genes Cells* 11:1281–1293.
16. Mohamed OA, HJ Clarke and D Dufort. (2004).  $\beta$ -catenin signaling marks the prospective site of primitive streak formation in the mouse embryo. *Dev Dyn* 231:416–424.
17. Gratsch TE, LS De Boer and KS O'Shea. (2003). RNA inhibition of BMP-4 gene expression in postimplantation mouse embryos. *Genesis* 37:12–17.
18. Pfaffl MW. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29:e45.
19. Wilkinson DG and MA Nieto. (1993). Detection of messenger RNA by *in situ* hybridization to tissue sections and whole mounts. *Methods Enzymol* 225:361–373.
20. Gong SG and C Guo. (2003). Bmp4 gene is expressed at the putative site of fusion in the midfacial region. *Differentiation* 71:228–236.
21. Shawlot W, JM Deng and RR Behringer. (1998). Expression of the mouse cerberus-related gene, Cerr1, suggests a role in anterior neural induction and somitogenesis. *Proc Natl Acad Sci USA* 95:6198–6203.
22. Davis CA, SE Noble-Topham, J Rossant and AL Joyner. (1988). Expression of the homeo box-containing gene En-2 delineates a specific region of the developing mouse brain. *Genes Dev* 2:361–371.
23. Hermesz E, S Mackem and KA Mahon. (1996). Rpx: a novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. *Development* 122:41–52.
24. Echelard Y, DJ Epstein, B St-Jacques, L Shen, J Mohler, JA McMahon and AP McMahon. (1993). Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. *Cell* 75:1417–1430.
25. Crossley PH and GR Martin. (1995). The mouse Fgf8 gene encodes a family of polypeptides and is expressed in regions that direct outgrowth and patterning in the developing embryo. *Development* 121:439–451.
26. Jowett AK, S Vainio, MWJ Ferguson, PT Sharpe and I Theisloff. (1993). Epithelial-mesenchymal interactions are required for msx 1 and msx 2 gene expression in the developing murine molar tooth. *Development* 117:461–470.
27. Fischer A, C Viebahn and M Blum. (2002). FGF8 acts as a right determinant during establishment of the left-right axis in the rabbit. *Curr Biol* 12:1807–1816.
28. Gratsch TE and KS O'Shea. (2002). Noggin and chordin have distinct activities in promoting lineage commitment of mouse embryonic stem (ES) cells. *Dev Biol* 245:83–94.
29. O'Shea KS, LS De Boer, NA Slawny and TE Gratsch. (2006). Transplacental RNAi: deciphering gene function in the postimplantation-staged embryo. *J Biomed Biotechnol* 4:18657.

30. Kwon GS, M Viotti and AK Hadjantonakis. (2008). The endoderm of the mouse embryo arises by dynamic widespread intercalation of embryonic and extraembryonic lineages. *Dev Cell* 15:509–520.
31. Solnica-Krezel L. (2005). Conserved patterns of cell movements during vertebrate gastrulation. *Curr Biol* 15:R213–R228.
32. Sauka-Spengler T and M Bronner-Fraser. (2008). A gene regulatory network orchestrates neural crest formation. *Nat Rev Mol Cell Biol* 9:557–568.
33. Seo S, A Herr, JW Lim, GA Richardson, H Richardson and KL Kroll. (2005). Geminin regulates neuronal differentiation by antagonizing Brg1 activity. *Genes Dev* 19:1723–1734.
34. Spella M, O Britz, P Kotantaki, Z Lygerou, H Nishitani, RG Ramsay, C Flordellis, F Guillemot, T Mantamadiotis and S Taraviras. (2007). Licensing regulators Geminin and Cdt1 identify progenitor cells of the mouse CNS in a specific phase of the cell cycle. *Neuroscience* 147:373–387.
35. Papanayotou C, A Mey, AM Birot, Y Saka, S Boast, JC Smith, J Samarut and CD Stern. (2008). A mechanism regulating the onset of Sox2 expression in the embryonic neural plate. *PLoS Biol* 6:e2.
36. Yanagi K, T Mizuno, T Tsuyama, S Tada, Y Lida, A Sugimoto, T Eki, T Enomoto and F Hanaoka. (2005). *Caenorhabditis elegans* geminin homologue participates in cell cycle regulation and germ line development. *J Biol Chem* 280:19689–19694.
37. Yang J and RA Weinberg. (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. *Dev Cell* 14:818–829.
38. Thiery JP, H Acloque, RY Huang and MA Nieto. (2009). Epithelial-mesenchymal transitions in development and disease. *Cell* 139:871–890.
39. Hay ED. (1995). An overview of epithelio-mesenchymal transformation. *Acta Anat* 154:8–20.
40. Li R, J Liang, S Ni, T Zhou, X Qing, H Li, W He, J Chen, F Li, et al. (2010). A Mesenchymal-to-Epithelial Transition Initiates and Is Required for the Nuclear Reprogramming of Mouse Fibroblasts. *Cell Stem Cell* 7:51–63.
41. Samavarchi-Tehrani P, A Golipour, L David, HK Sung, TA Beyer, A Datti, K Woltjen, A Nagy and JL Wrana. (2010). Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. *Cell Stem Cell* 7:64–77.
42. Kemler R, A Hierholzer, B Kanzler, S Kuppig, K Hansen, MM Taketo, WN de Vries, BB Knowles and D Solter. (2004). Stabilization of beta-catenin in the mouse zygote leads to premature epithelial-mesenchymal transition in the epiblast. *Development* 131:5817–5824.
43. Roberts C, HF Sutherland, H Farmer, W Kimber, S Halford, A Carey, JM Brickman, A Wynshaw-Boris and PJ Scambler. (2002). Targeted mutagenesis of the Hira gene results in gastrulation defects and patterning abnormalities of mesodermal derivatives prior to early embryonic lethality. *Mol Cell Biol* 22:2318–2328.
44. Deng CX, A Wynshaw-Boris, MM Shen, C Daugherty, DM Ornitz and P Leder. (1994). Murine FGFR-1 is required for early postimplantation growth and axial organization. *Genes Dev* 8:3045–3057.
45. Yamaguchi TP, K Harpal, M Henkemeyer and J Rossant J. (1994). *fgfr-1* is required for embryonic growth and mesodermal patterning during mouse gastrulation. *Genes Dev* 8:3032–3044.
46. Sun X, EN Meyers, M Lewandoski and GR Martin. (1999). Targeted disruption of *Fgf8* causes failure of cell migration in the gastrulating mouse embryo. *Genes Dev* 13:1834–1846.
47. Arnold SJ, UK Hofmann, EK Bikoff and EJ Robertson. (2008). Pivotal roles for eomesodermin during axis formation, epithelium-to-mesenchyme transition and endoderm specification in the mouse. *Development* 135:501–511.
48. Carver EA, R Jiang, Y Lan, KF Oram and T Gridley. (2001). The mouse snail gene encodes a key regulator of the epithelial-mesenchymal transition. *Mol Cell Biol* 21:8184–8188.
49. Liu X, S Huang, J Ma, C Li, Y Zhang and L Luo. (2009). NF-kappa B and Snail1 coordinate the cell cycle with gastrulation. *J Cell Biol* 184:805–815.
50. Tam PP and DA Loebel. (2007). Gene function in mouse embryogenesis: get set for gastrulation. *Nat Rev Genet* 8:368–381.
51. Placzek M, J Dodd and TM Jessell. (2000). The case for floor plate induction by the notochord. *Curr Opin Neurobiol* 10:15–22.
52. Ybot-Gonzalez P, C Gaston-Massuet, G Girdler, J Klingensmith, R Arkell, ND Greene and AJ Copp. (2007). Neural plate morphogenesis during mouse neurulation is regulated by antagonism of Bmp signaling. *Development* 134:3203–3211.
53. Duband JL. (2006). Neural crest delamination and migration: integrating regulations of cell interactions, locomotion, survival, and fate. *Adv Exp Med Biol* 589:45–77.
54. Anderson RM, RW Stottmann, M Choi and J Klingensmith. (2006). Endogenous bone morphogenetic protein antagonists regulate mammalian neural crest generation and survival. *Dev Dyn* 235:2507–2520.
55. Raible DW. (2006). Development of the neural crest: achieving specificity in regulatory pathways. *Curr Opin Cell Biol* 18:698–703.
56. Patthey C, T Edlund and L Gunhaga. (2009). Wnt-regulated temporal control of BMP exposure directs the choice between neural plate border and epidermal fate. *Development* 136:73–83.
57. Steventon B, C Araya, C Linker, S Kuriyama and R Mayor. (2009). Differential requirements of BMP and Wnt signalling during gastrulation and neurulation define two steps in neural crest induction. *Development* 136:771–779.
58. Hussein SM, EK Duff and C Sirard. (2003). Smad4 and beta-catenin co-activators functionally interact with lymphoid-enhancing factor to regulate graded expression of Msx2. *J Biol Chem* 278:48805–48814.
59. Conacci-Sorrell M, I Simcha, T Ben-Yedidia, J Blechman, P Savagner and A Ben-Ze'ev. (2003). Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signaling, Slug, and MAPK. *J Cell Biol* 163:847–857.
60. Burstyn-Cohen T, J Stanleigh, D Sela-Donenfeld and C Kalcheim. (2004). Canonical Wnt activity regulates trunk neural crest delamination linking BMP/noggin signaling with G1/S transition. *Development* 131:5327–5339.
61. Burstyn-Cohen T and C Kalcheim. (2002). Association between the cell cycle and neural crest delamination through specific regulation of G1/S transition. *Dev Cell* 3:383–395.
62. Spella M, C Kyrrousi, E Kritikou, A Stathopoulou, F Guillemot, D Kioussis, V Pachnis, Z Lygerou and S Taraviras. (2011). Geminin regulates cortical progenitor proliferation and differentiation. *Stem Cells* 29:1269–1282.
63. Doble BW, S Patel, GA Wood, LK Kockeritz and JR Woodgett. (2007). Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. *Dev Cell* 12:957–971.



64. Haegel H, L Larue, M Ohsugi, L Fedorov, K Herrenknecht and R Kemler. (1995). Lack of  $\beta$ -catenin affects mouse development at gastrulation. *Development* 121:3529–3537.
65. Popperl H, C Schmidt, V Wilson, CR Hume, J Dodd, R Krumlauf and RS Beddington. (1997). Misexpression of *Cwnt8c* in the mouse induces an ectopic embryonic axis and causes a truncation of the anterior neuroectoderm. *Development* 124:2997–3005.
66. Ishikawa TO, Y Tamai, Q Li, M Oshima and MM Taketo. (2003). Requirement for tumor suppressor *Apc* in the morphogenesis of anterior and ventral mouse embryo. *Dev Biol* 253:230–246.
67. Zeng L, F Fagotto, T Zhang, W Hsu, TJ Vasicek, WL Perry 3rd, JJ Lee, SM Tilghman, BM Gumbiner and F Costantini. (1997). The mouse *Fused* locus encodes Axin, an inhibitor of the Wnt signaling pathway that regulates embryonic axis formation. *Cell* 90:181–192.
68. Merrill BJ, HA Pasoli, L Polak, M Rendl, MJ Garcia-Garcia, KV Anderson and E Fuchs. (2004). *Tcf3*: a transcriptional regulator of axis induction in the early embryo. *Development* 131:263–274.
69. Taylor JJ, T Wang and KL Kroll. (2006). *Tcf*- and *Vent*-binding sites regulate neural-specific *geminin* expression in the gastrula embryo. *Dev Biol* 289:494–506.
70. Stemmer V, B de Craene, G Berx and J Behrens. (2008). *Snail* promotes Wnt target gene expression and interacts with *beta*-catenin. *Oncogene* 27:5075–5080.
71. Mishina Y, A Suzuki, N Ueno and RR Behringer. (1995). *Bmpr* encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. *Genes Development* 9:3027–3037.
72. Fujiwara T, DB Dehart, KK Sulik and BL Hogan. (2002). Distinct requirements for extra-embryonic and embryonic bone morphogenetic protein 4 in the formation of the node and primitive streak and coordination of left-right asymmetry in the mouse. *Development* 129:4685–4696.
73. Rogers CD, N Harafuji, T Archer, DD Cunningham and ES Casey. (2009). *Xenopus Sox3* activates *sox2* and *geminin* and indirectly represses *Xvent2* expression to induce neural progenitor formation at the expense of non-neural ectodermal derivatives. *Mech Dev* 126:42–55.
74. Luo L and M Kessel. (2004). *Geminin* coordinates cell cycle and developmental control. *Cell Cycle* 3:711–714.
75. Schultz KM, G Banisadr, RO Lastra, T McGuire, JA Kessler, RJ Miller and TJ McGarry. (2011). *Geminin*-deficient neural stem cells exhibit normal cell division and normal neurogenesis. *PLoS One* 6:e17736.
76. Seo S, GA Richardson and KL Kroll. (2005b). The SWI/SNF chromatin remodeling protein *Brg1* is required for vertebrate neurogenesis and mediates transactivation of *Ngn* and *NeuroD*. *Development* 132:105–115.
77. Park JJ, AS Venteicher, JY Hong, J Choi, S Jun, M Shkrel, W Chang, Z Meng, P Cheung, et al. (2009). Telomerase modulates Wnt signaling by association with target gene chromatin. *Nature* 460:66–72.
78. Barker N, A Hurlstone, H Musisi, A Miles, M Bienz and H Clevers. (2001). The chromatin remodeling factor *Brg-1* interacts with *beta*-catenin to promote target gene activation. *EMBO J* 20:4935–4943.
79. Eroglu B, G Wang, N Tu, X Sun and NF Mivechi. (2006). Critical role of *Brg1* member of the SWI/SNF chromatin remodeling complex during neurogenesis and neural crest induction in zebrafish. *Dev Dyn* 235:2722–2735.

Address correspondence to:

*Dr. K. Sue O'Shea*

*Department of Cell and Developmental Biology*

*University of Michigan*

*3051 A. Alfred Taubman Basic Science Research Building*

*109 Zina Pitcher Place*

*Ann Arbor, MI 48109-2200*

*E-mail: oshea@umich.edu*

Received for publication August 24, 2011

Accepted after revision February 14, 2012

Prepublished on Liebert Instant Online February 16, 2012

**This article has been cited by:**

1. Nicole Slawny, K. Sue O'Shea. 2013. Geminin Promotes an Epithelial-to-Mesenchymal Transition in an Embryonic Stem Cell Model of Gastrulation. *Stem Cells and Development* **22**:8, 1177-1189. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]